Filing Details
- Accession Number:
- 0001209191-23-024227
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-13 17:13:18
- Reporting Period:
- 2023-04-11
- Accepted Time:
- 2023-04-13 17:13:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1607678 | Viking Therapeutics Inc. | VKTX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1264949 | Greg Zante | C/O Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego CA 92121 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-04-11 | 3,242 | $7.77 | 152,521 | No | 4 | M | Direct | |
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-04-11 | 8,500 | $4.68 | 161,021 | No | 4 | M | Direct | |
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-04-11 | 30,000 | $4.88 | 191,021 | No | 4 | M | Direct | |
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-04-11 | 14,553 | $5.80 | 205,574 | No | 4 | M | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2023-04-11 | 56,295 | $18.00 | 149,279 | No | 4 | S | Direct | |
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-04-12 | 37,447 | $5.80 | 186,726 | No | 4 | M | Direct | |
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-04-12 | 4,097 | $7.77 | 190,823 | No | 4 | M | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2023-04-12 | 41,544 | $18.00 | 149,279 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2023-04-11 | 3,242 | $0.00 | 3,242 | $7.77 |
Common Stock | Stock Option (right to buy | Disposition | 2023-04-11 | 8,500 | $0.00 | 8,500 | $4.68 |
Common Stock | Stock Option (right to buy | Disposition | 2023-04-11 | 30,000 | $0.00 | 30,000 | $4.88 |
Common Stock | Stock Option (right to buy | Disposition | 2023-04-11 | 14,553 | $0.00 | 14,553 | $5.80 |
Common Stock | Stock Option (right to buy | Disposition | 2023-04-12 | 37,447 | $0.00 | 37,447 | $5.80 |
Common Stock | Stock Option (right to buy) | Disposition | 2023-04-12 | 4,097 | $0.00 | 4,097 | $7.77 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
16,847 | 2021-01-03 | 2030-01-03 | No | 4 | M | Direct |
8,500 | 2021-03-31 | 2030-03-31 | No | 4 | M | Direct |
90,000 | 2023-01-03 | 2032-01-03 | No | 4 | M | Direct |
63,447 | 2022-01-04 | 2031-01-04 | No | 4 | M | Direct |
26,000 | 2022-01-04 | 2031-01-04 | No | 4 | M | Direct |
12,750 | 2021-01-03 | 2030-01-03 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person.
- 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date.
- The Form 4 filed by the Reporting Person on April 3, 2023 reporting, among other things, the exercise of 30,911 shares subject to this option on April 3, 2023 inadvertently indicated that there were 0 shares remaining subject to this option after such exercise. That Form 4 should have reflected that there were 20,089 shares remaining subject to this option after such exercise and the balance has been adjusted accordingly in this Form 4.
- One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date.